Metyrosine is under clinical development by Yamo Pharmaceuticals and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Metyrosine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metyrosine overview

L-179 (metyrosine) is under development for the treatment of autism. The drug candidate is administered through oral route as a capsule. It is a racemic form of the drug Demser. The drug candidate acts by targeting Tyrosine 3 Monooxygenase.

Yamo Pharmaceuticals overview

Yamo Pharmaceuticals is a Pharmaceuticals and Healthcare company that provides novel therapy that targets the core symptoms of autism. The company is Headquartered in New York, The U.S.

For a complete picture of Metyrosine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.